Melatonin enhances arsenic trioxide-induced cell death via sustained upregulation of Redd1 expression in breast cancer cells

Molecular and Cellular Endocrinology

Volumn 422, Issue , 2016, Pages 64-73

  Yun, Sun Mi ^a   Woo, Sang Hyeok ^a   Oh, Sang Taek ^b   Hong, Sung Eun ^a   Choe, Tae Boo ^c   Ye, Sang Kyu ^d   Kim, Eun Kyu ^e   Seong, Min Ki ^f   Kim, Hyun A ^f   Noh, Woo Chul ^f   Lee, Jin Kyung ^a   Jin, Hyeon Ok ^a   Lee, Yun Han ^b   Park, In Chul ^a  

^a Korea Institute of Radiation and Medical Science   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

^c Konkuk University   (South Korea)

^d Seoul National University College of Medicine   (South Korea)

^e Seoul National University Bundang Hospital   (South Korea)

^f Korea Cancer Center Hospital   (South Korea)

Author keywords

Apoptotic cell death; Arsenic trioxide; Melatonin; MTORC1; Redd1

Indexed keywords

ARSENIC TRIOXIDE; CYTOCHROME C; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MELATONIN; MITOGEN ACTIVATED PROTEIN KINASE P38; ONCOPROTEIN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN REDD1; RAPAMYCIN; REACTIVE OXYGEN METABOLITE; SMALL INTERFERING RNA; STRESS ACTIVATED PROTEIN KINASE; SURVIVIN; TUBERIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; DDIT4 PROTEIN, HUMAN; ORGANOARSENIC DERIVATIVE; OXIDE; TRANSCRIPTION FACTOR;

ANALYTICAL PARAMETERS; APOPTOSIS; ARTICLE; BREAST CANCER CELL LINE; CANCER CELL LINE; CELL DEATH; CELL VIABILITY; COMBINATION INDEX; CONTROLLED STUDY; CYTOSOL; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; MDA MB 231 CELL; MTT ASSAY; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN SECRETION; SK BR 3 CELL; UPREGULATION; BREAST TUMOR; CELL SURVIVAL; DRUG EFFECTS; DRUG POTENTIATION; FEMALE; GENE EXPRESSION REGULATION; METABOLISM; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; ARSENICALS; BREAST NEOPLASMS; CELL DEATH; CELL LINE, TUMOR; CELL SURVIVAL; DRUG SYNERGISM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MAP KINASE SIGNALING SYSTEM; MELATONIN; OXIDES; TRANSCRIPTION FACTORS; UP-REGULATION;

EID: 84961369187     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2015.11.016     Document Type: Article

References (40)

1. Alarifi S., Ali D., Alkahtani S., Siddiqui M.A., Ali B.A. Arsenic trioxide-mediated oxidative stress and genotoxicity in human hepatocellular carcinoma cells. Onco Targets Ther. 2013, 6:75-84.
2. Antman K.H. Introduction: the history of arsenic trioxide in cancer therapy. Oncologist 2001, 6(Suppl. 2):1-2.
3. Bartsch H., Buchberger A., Franz H., Bartsch C., Maidonis I., Mecke D., Bayer E. Effect of melatonin and pineal extracts on human ovarian and mammary tumor cells in a chemosensitivity assay. Life Sci. 2000, 67:2953-2960.
4. Bejarano I., Espino J., Barriga C., Reiter R.J., Pariente J.A., Rodriguez A.B. Pro-oxidant effect of melatonin in tumour leucocytes: relation with its cytotoxic and pro-apoptotic effects. Basic Clin. Pharmacol. Toxicol. 2011, 108:14-20.
5. Brugarolas J., Lei K., Hurley R.L., Manning B.D., Reiling J.H., Hafen E., Witters L.A., Ellisen L.W., Kaelin W.G. Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex. Genes Dev. 2004, 18:2893-2904.
6. Burdon R.H. Control of cell proliferation by reactive oxygen species. Biochem. Soc. Trans. 1996, 24:1028-1032.
7. Cabrera J., Negrin G., Estevez F., Loro J., Reiter R.J., Quintana J. Melatonin decreases cell proliferation and induces melanogenesis in human melanoma SK-MEL-1 cells. J. Pineal Res. 2010, 49:45-54.
8. Cassone V.M. Effects of melatonin on vertebrate circadian systems. Trends Neurosci. 1990, 13:457-464.
9. Chou T.C., Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 1984, 22:27-55.
10. Corradetti M.N., Inoki K., Guan K.L. The stress-inducted proteins RTP801 and RTP801L are negative regulators of the mammalian target of rapamycin pathway. J. Biol. Chem. 2005, 280:9769-9772.
11. Cos S., Sanchez-Barcelo E.J. Melatonin, experimental basis for a possible application in breast cancer prevention and treatment. Histol. Histopathol. 2000, 15:637-647.
12. Davies H.M. Ex vivo calibration and validation of in vivo equine bone strain measures. Equine Vet. J. 2009, 41:225-228.
13. Ellisen L.W., Ramsayer K.D., Johannessen C.M., Yang A., Beppu H., Minda K., Oliner J.D., McKeon F., Haber D.A. REDD1, a developmentally regulated transcriptional target of p63 and p53, links p63 to regulation of reactive oxygen species. Mol. Cell. 2002, 10:995-1005.
14. Fan L.L., Sun G.P., Wei W., Wang Z.G., Ge L., Fu W.Z., Wang H. Melatonin and doxorubicin synergistically induce cell apoptosis in human hepatoma cell lines. World J. Gastroenterol. 2010, 16:1473-1481.
15. Fic M., Podhorska-Okolow M., Dziegiel P., Gebarowska E., Wysocka T., Drag-Zalesinska M., Zabel M. Effect of melatonin on cytotoxicity of doxorubicin toward selected cell lines (human keratinocytes, lung cancer cell line A-549, laryngeal cancer cell line Hep-2). Vivo 2007, 21:513-518.
16. Hassan M.I., Ahmed M.I., Kassim S.K., Rashad A., Khalifa A. Cis-platinum-induced immunosuppression: relationship to melatonin in human peripheral blood mononuclear cells. Clin. Biochem. 1999, 32:621-626.
17. Ingram D.G., Matthews C.K., Plante D.T. Seasonal trends in sleep-disordered breathing: evidence from Internet search engine query data. Sleep. Breath. 2015, 19:79-84.
18. Jin H.O., Seo S.K., Woo S.H., Kim E.S., Lee H.C., Yoo D.H., An S., Choe T.B., Lee S.J., Hong S.I., Rhee C.H., Kim J.I., Park I.C. Activating transcription factor 4 and CCAAT/enhancer-binding protein-beta negatively regulate the mammalian target of rapamycin via Redd1 expression in response to oxidative and endoplasmic reticulum stress. Free Radic. Biol. Med. 2009, 46:1158-1167.
19. Jin H.O., Seo S.K., Woo S.H., Lee H.C., Kim E.S., Yoo D.H., Lee S.J., An S., Choe T.B., Kim J.I., Hong S.I., Rhee C.H., Park I.C. A combination of sulindac and arsenic trioxide synergistically induces apoptosis in human lung cancer H1299 cells via c-Jun NH2-terminal kinase-dependent Bcl-xL phosphorylation. Lung Cancer 2008, 61:317-327.
20. Jin H.O., Yoon S.I., Seo S.K., Lee H.C., Woo S.H., Yoo D.H., Lee S.J., Choe T.B., An S., Kwon T.J., Kim J.I., Park M.J., Hong S.I., Park I.C., Rhee C.H. Synergistic induction of apoptosis by sulindac and arsenic trioxide in human lung cancer A549 cells via reactive oxygen species-dependent down-regulation of survivin. Biochem. Pharmacol. 2006, 72:1228-1236.
21. Kasukabe T., Okabe-Kado J., Haranosono Y., Kato N., Honma Y. Inhibition of rapamycin-induced Akt phosphorylation by cotylenin A correlates with their synergistic growth inhibition of cancer cells. Int. J. Oncol. 2013, 42:767-775.
22. Kasukabe T., Okabe-Kado J., Kato N., Honma Y., Kumakura S. Cotylenin A and arsenic trioxide cooperatively suppress cell proliferation and cell invasion activity in human breast cancer cells. Int. J. Oncol. 2015, 46:841-848.
23. Kim J.H., Jeong S.J., Kim B., Yun S.M., Choi do Y., Kim S.H. Melatonin synergistically enhances cisplatin-induced apoptosis via the dephosphorylation of ERK/p90 ribosomal S6 kinase/heat shock protein 27 in SK-OV-3 cells. J. Pineal Res. 2012, 52:244-252.
24. Lissoni P., Barni S., Mandala M., Ardizzoia A., Paolorossi F., Vaghi M., Longarini R., Malugani F., Tancini G. Decreased toxicity and increased efficacy of cancer chemotherapy using the pineal hormone melatonin in metastatic solid tumour patients with poor clinical status. Eur. J. Cancer 1999, 35:1688-1692.
25. Li W., Wang M., Wang L., Ji S., Zhang J., Zhang C. Icariin synergizes with arsenic trioxide to suppress human hepatocellular carcinoma. Cell Biochem. Biophys. 2014, 68:427-436.
26. Luo L., Qiao H., Meng F., Dong X., Zhou B., Jiang H., Kanwar J.R., Krissansen G.W., Sun X. Arsenic trioxide synergizes with B7H3-mediated immunotherapy to eradicate hepatocellular carcinomas. Int. J. Cancer 2006, 118:1823-1830.
27. Mann K.K., Colombo M., Miller W.H. Arsenic trioxide decreases AKT protein in a caspase-dependent manner. Mol. Cancer Ther. 2008, 7:1680-1687.
28. Miller W.H., Schipper H.M., Lee J.S., Singer J., Waxman S. Mechanisms of action of arsenic trioxide. Cancer Res. 2002, 62:3893-3903.
29. Radogna F., Paternoster L., De Nicola M., Cerella C., Ammendola S., Bedini A., Tarzia G., Aquilano K., Ciriolo M., Ghibelli L. Rapid and transient stimulation of intracellular reactive oxygen species by melatonin in normal and tumor leukocytes. Toxicol. Appl. Pharmacol. 2009, 239:37-45.
30. Reiling J.H., Hafen E. The hypoxia-induced paralogs Scylla and Charybdis inhibit growth by down-regulating S6K activity upstream of TSC in Drosophila. Genes Dev. 2004, 18:2879-2892.
31. Reiter R.J. Mechanisms of cancer inhibition by melatonin. J. Pineal Res. 2004, 37:213-214.
32. Reiter R.J., Tan D.X., Sainz R.M., Mayo J.C., Lopez-Burillo S. Melatonin: reducing the toxicity and increasing the efficacy of drugs. J. Pharm. Pharmacol. 2002, 54:1299-1321.
33. Rogers C.S., Yedjou C.G., Sutton D.J., Tchounwou P.B. Vitamin D3 potentiates the antitumorigenic effects of arsenic trioxide in human leukemia (HL-60) cells. Exp. Hematol. Oncol. 2014, 3:9.
34. Rondanelli M., Faliva M.A., Perna S., Antoniello N. Update on the role of melatonin in the prevention of cancer tumorigenesis and in the management of cancer correlates, such as sleep-wake and mood disturbances: review and remarks. Aging Clin. Exp. Res. 2013, 25:499-510.
35. Sainz R.M., Mayo J.C., Rodriguez C., Tan D.X., Lopez-Burillo S., Reiter R.J. Melatonin and cell death: differential actions on apoptosis in normal and cancer cells. Cell Mol. Life Sci. 2003, 60:1407-1426.
36. Shoshani T., Faerman A., Mett I., Zelin E., Tenne T., Gorodin S., Moshel Y., Elbaz S., Budanov A., Chajut A., Kalinski H., Kamer I., Rozen A., Mor O., Keshet E., Leshkowitz D., Einat P., Skaliter R., Feinstein E. Identification of a novel hypoxia-inducible factor 1-responsive gene, RTP801, involved in apoptosis. Mol. Cell Biol. 2002, 22:2283-2293.
37. Stehle J.H., Saade A., Rawashdeh O., Ackermann K., Jilg A., Sebesteny T., Maronde E. A survey of molecular details in the human pineal gland in the light of phylogeny, structure, function and chronobiological diseases. J. Pineal Res. 2011, 51:17-43.
38. Uguz A.C., Cig B., Espino J., Bejarano I., Naziroglu M., Rodriguez A.B., Pariente J.A. Melatonin potentiates chemotherapy-induced cytotoxicity and apoptosis in rat pancreatic tumor cells. J. Pineal Res. 2012, 53:91-98.
39. Zhang Y.F., Zhang M., Huang X.L., Fu Y.J., Jiang Y.H., Bao L.L., Maimaitiyiming Y., Zhang G.J., Wang Q.Q., Naranmandura H. The combination of arsenic and cryptotanshinone induces apoptosis through induction of endoplasmic reticulum stress-reactive oxygen species in breast cancer cells. Metallomics 2015, 7:165-173.
40. Zhao X.Y., Yang S., Chen Y.R., Li P.C., Dou M.M., Zhang J. Resveratrol and arsenic trioxide act synergistically to kill tumor cells in vitro and in vivo. PLoS One 2014, 9:e98925.